Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
A Study To Evaluate Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Generalized Myasthenia Gravis
- Conditions
- Interventions
- First Posted Date
- 2021-07-15
- Last Posted Date
- 2024-10-04
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 188
- Registration Number
- NCT04963270
- Locations
- 🇺🇸
Keck School of Medicine of USC, Los Angeles, California, United States
🇺🇸SC3 Research Group, Inc, Pasadena, California, United States
🇺🇸Childrens National Health Center, Washington, District of Columbia, United States
A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)
- Conditions
- Interventions
- First Posted Date
- 2021-07-14
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 4200
- Registration Number
- NCT04961996
- Locations
- 🇺🇸
Centra Alan B. Pearson Regional Cancer Center, Lynchburg, Virginia, United States
🇬🇷University of Athens, Hematological Clinic,; First Department of Propaedeutic Medicine, Athens, Greece
🇺🇸Southern Cancer Center, Daphne, Alabama, United States
A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
- First Posted Date
- 2021-07-12
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT04958265
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center; Investigational Drug Services, Cincinnati, Ohio, United States
🇮🇳All India Institute Of Medical Sciences (AIIMS), New Delhi, Delhi, India
🇺🇸UT Health Science Center; SouthTexas Pediatric Blood and Cancer Ctr, San Antonio, Texas, United States
A Study to Explore the Efficacy and Safety of Atezolizumab Plus Tiragolumab and Chemotherapy in 1st Line HER2 Negative Unresectable, Recurrent or Metastatic Gastric Cancer or Adenocarcinoma of Gastroesophageal Junction (GEJ)
- Conditions
- Interventions
- First Posted Date
- 2021-06-21
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 29
- Registration Number
- NCT04933227
- Locations
- 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, China
🇨🇳Jilin Cancer Hospital, Changchun, China
🇨🇳Beijing Cancer Hospital, Beijing, China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors
- Conditions
- Interventions
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 176
- Registration Number
- NCT04931342
- Locations
- 🇫🇷
CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France
🇫🇷Institut Bergonie; Oncologie, Bordeaux, France
🇫🇷Centre Francois Baclesse; Oncologie, Caen, France
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
- First Posted Date
- 2021-06-18
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 542
- Registration Number
- NCT04929223
- Locations
- 🇺🇸
cCare, Encinitas, California, United States
🇺🇸Los Angeles Cancer Network, Los Angeles, California, United States
🇺🇸Hoag Memorial Hospital Presbyterian, Newport Beach, California, United States
A Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Crovalimab for the Management of Acute Uncomplicated Vaso-Occlusive Episodes (VOE) in Participants With Sickle Cell Disease (SCD).
- First Posted Date
- 2021-06-03
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 30
- Registration Number
- NCT04912869
- Locations
- 🇺🇸
Children'S Healthcare of Atlanta, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Michigan; Pediatrics, Detroit, Michigan, United States
🇺🇸Icahn School of Medicine at Mount Sinai, New York, New York, United States
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 216
- Registration Number
- NCT04889040
- Locations
- 🇯🇵
Higashiosaka city Medical Center, Higashiosaka-Shi, Japan
🇷🇴County Hospital Caracal, Caracal, Romania
🇧🇪Maison Médicale La Brèche, Châtelineau, Belgium
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
- Conditions
- Interventions
- First Posted Date
- 2021-05-05
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 1150
- Registration Number
- NCT04873362
- Locations
- 🇺🇸
Alabama Oncology, Alabaster, Alabama, United States
🇺🇸Roy and Patricia Disney Family Cancer Center- Providence Saint Joseph Medical Center, Burbank, California, United States
🇺🇸Innovation Clinical Research Institute, Cerritos, California, United States
A Study To Assess Distribution Of RO7248824 In The Central Nervous System Following Single Intrathecal Doses Of [89zr] Labeled RO7248824 In Healthy Male Participants
- First Posted Date
- 2021-04-28
- Last Posted Date
- 2022-09-08
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 21
- Registration Number
- NCT04863794
- Locations
- 🇳🇱
Pra International Group B.V, Groningen, Netherlands